Formula Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Formula Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014234
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Formula Pharmaceuticals Inc (Formula Pharmaceuticals) is an oncology company that develops chimeric antigen receptor (CAR) immunotherapy for oncology and autoimmune diseases. The company’s pipeline products include CIK-CAR.CD19, used as B-lymphocyte surface antigen; CIK-CAR.CD33, used for the treatment of myeloid leukemias; and CIK-CAR.PSMA. Its CAR technology platform helps to increase the patient access, clinical benefit potential, and reduce the cost of manufacturing. Formula Pharmaceuticals also develops proprietary and licensed therapies in the field of hematologic oncology and solid tumor indications in collaboration with the other organizations. Formula Pharmaceuticals is headquartered in Berwyn, Pennsylvania, the US.

Formula Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Formula Pharma To Secure US$13 Million In Series B Financing 10
Formula Pharma Raises US$1.5 Million In Series A Financing 11
Partnerships 12
Formula Pharma Enters into Co-Development Agreement with Rockland Immunochemicals 12
Licensing Agreements 13
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 13
Formula Pharma Enters into Licensing Agreement with Research Center Fondazione M.Tettamanti 14
Equity Offering 15
Formula Pharma Raises Funds through Private Placement 15
Formula Pharmaceuticals Inc – Key Competitors 16
Formula Pharmaceuticals Inc – Key Employees 17
Formula Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Formula Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Formula Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Formula Pharma To Secure US$13 Million In Series B Financing 10
Formula Pharma Raises US$1.5 Million In Series A Financing 11
Formula Pharma Enters into Co-Development Agreement with Rockland Immunochemicals 12
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 13
Formula Pharma Enters into Licensing Agreement with Research Center Fondazione M.Tettamanti 14
Formula Pharma Raises Funds through Private Placement 15
Formula Pharmaceuticals Inc, Key Competitors 16
Formula Pharmaceuticals Inc, Key Employees 17

★海外企業調査レポート[Formula Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Deutsche Ruckversicherung AG:企業の戦略・SWOT・財務情報
    Deutsche Ruckversicherung AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Ruckversicherung AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Apexigen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company t hat focuses on discovery and development of antibody-based drugs for the treatment of cancer.The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell r …
  • Axikin Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Axikin Pharmaceuticals Inc (Axikin) is a biopharmaceutical company that develops small molecule therapeutics for respiratory disorders. The company offers pre-clinical and research programs with small molecule therapeutics for applications in asthma, chronic obstructive pulmonary disease, in …
  • Lite-On Technology Corp (2301):企業の財務・戦略的SWOT分析
    Lite-On Technology Corp (2301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • GridEdge Networks Inc:企業の戦略的SWOT分析
    GridEdge Networks Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Beckman Coulter Inc-医療機器分野:企業M&A・提携分析
    Summary Beckman Coulter Inc (Beckman) is a manufacturer of biomedical testing instrument systems. It develops, manufactures and markets biomedical laboratory instruments, software and other things that simplify and automate complex biomedical tests. The company’s products are used in a wide range of …
  • F. Hoffmann-La Roche Ltd (ROG):医療機器:M&Aディール及び事業提携情報
    Summary F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, ne …
  • AFGlobal Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary AFGlobal Corp (AFGlobal), formerly Ameriforge Group Inc is an engineering service provider that offers manufacturing, technology and precision engineering services. The company's services comprise forging, welding, machining, heat treat, fabrication and assembly, and testing and inspection. …
  • Extendicare Inc (EXE):企業の財務・戦略的SWOT分析
    Summary Extendicare Inc (Extendicare), formerly Crownx Inc is a healthcare service provider that offers long-term care services. The center’s services include short stay care, convalescent care, home health care, group purchasing, assisted living, retirement living, workplace health and wellness, sk …
  • Zhejiang Xianju Pharmaceutical Co Ltd (002332):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Xianju Pharmaceutical Co Ltd (Zhejiang Xianju Pharmaceutical) is a contract manufacturer of API and formulations. The company offers products such as ingredients, active pharmaceutical ingredients, steroids and hormones, pharmaceutical products, and finished formulations, among othe …
  • Mayne Pharma Group Ltd (MYX):企業の財務・戦略的SWOT分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma) formerly HalcyGen Pharmaceuticals Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company offers products such as erymax capsules, kapanol capsules, doryx capsules, magnoplasm, astrix c …
  • Midatech Pharma Plc (MTPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimm …
  • General Electric Company:企業の戦略・SWOT・財務情報
    General Electric Company - Strategy, SWOT and Corporate Finance Report Summary General Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Software AG (SOW):企業の財務・戦略的SWOT分析
    Summary Software AG (SAG) is a technology company that provides software management solutions. The company offers digital business platform with integration, process management, adaptive application development, real-time analytics and enterprise architecture management. Its products include Adabas …
  • Saniona AB (SANION):企業の財務・戦略的SWOT分析
    Summary Saniona AB (Saniona) formerly Aniona, is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company’s pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which …
  • Cellular Biomedicine Group Inc (CBMG):企業の財務・戦略的SWOT分析
    Summary Cellular Biomedicine Group Inc (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of …
  • Fujikura Ltd.:企業の戦略・SWOT・財務分析
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • HIL Limited (HIL):企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SAS Group:戦略・SWOT・企業財務分析
    SAS Group - Strategy, SWOT and Corporate Finance Report Summary SAS Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆